Image Katrin Andreasson Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences Affiliation: Knight Initiative Funded Researchers Wu Tsai Neuro Faculty Affiliates View Stanford Profile Related Links Neurology Andreasson Lab Site Stanford Alzheimer's Disease Research Center Related Projects Wu Tsai Neurosciences Institute Neuroscience:Translate Award 2022 Development and validation of selective novel small molecule therapeutics for Parkinson's Disease Wu Tsai Neurosciences Institute Neuroscience:Translate Award 2020 Targeting DNA repair for neuroinflammation in stroke Wu Tsai Neurosciences Institute Seed Grant 2015 A novel PET radioligand to identify microglial inflammation in Alzheimer's disease Pagination First page Previous page Page 1 Current page 2 Page 3 Page 4 Page 5 Next page Last page Related News More News Image Research news | Aug 13 2025 Knight Initiative for Brain Resilience Parkinson’s comes in many forms. New biomarkers may explain why Blood and cerebrospinal fluid markers tied to inflammation and metabolism sort some patients into subgroups, according to Knight Initiative researchers, a step toward predicting progression and tailoring care. Image Awards and honors | Jul 27 2025 Alzheimer's Association Alzheimer's Association honors Katrin Andreasson Andreasson received the Inge Grundke-Iqbal Award for her work on restoring cognition in Alzheimer's. Karly Cody, a postdoctoral fellow in the lab of Knight Initiative researcher Elizabeth Mormino, was also honored. Image Researcher profiles | Jan 27 2025 Knight Initiative for Brain Resilience Q&A: Unraveling the role of endocannabinoid metabolism in brain aging Research supported by a Knight Initiative Catalyst Grant explores whether targeting pathways related to the brain’s “chill-out” system could restore youthful resilience and improve cognitive function. Image Press coverage | Sep 2 2024 NPR This metabolic brain boost revives memory in Alzheimer’s mice Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques. Pagination First page Previous page Page 1 Current page 2 Page 3 Page 4 Page 5 Next page Last page
Wu Tsai Neurosciences Institute Neuroscience:Translate Award 2022 Development and validation of selective novel small molecule therapeutics for Parkinson's Disease
Wu Tsai Neurosciences Institute Neuroscience:Translate Award 2020 Targeting DNA repair for neuroinflammation in stroke
Wu Tsai Neurosciences Institute Seed Grant 2015 A novel PET radioligand to identify microglial inflammation in Alzheimer's disease
Image Research news | Aug 13 2025 Knight Initiative for Brain Resilience Parkinson’s comes in many forms. New biomarkers may explain why Blood and cerebrospinal fluid markers tied to inflammation and metabolism sort some patients into subgroups, according to Knight Initiative researchers, a step toward predicting progression and tailoring care.
Image Awards and honors | Jul 27 2025 Alzheimer's Association Alzheimer's Association honors Katrin Andreasson Andreasson received the Inge Grundke-Iqbal Award for her work on restoring cognition in Alzheimer's. Karly Cody, a postdoctoral fellow in the lab of Knight Initiative researcher Elizabeth Mormino, was also honored.
Image Researcher profiles | Jan 27 2025 Knight Initiative for Brain Resilience Q&A: Unraveling the role of endocannabinoid metabolism in brain aging Research supported by a Knight Initiative Catalyst Grant explores whether targeting pathways related to the brain’s “chill-out” system could restore youthful resilience and improve cognitive function.
Image Press coverage | Sep 2 2024 NPR This metabolic brain boost revives memory in Alzheimer’s mice Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques.